D. Boral Capital Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They presently have a $10.00 price target on the stock. D. Boral Capital’s price objective would suggest a potential upside of 338.60% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, November 19th.

Anixa Biosciences Trading Up 7.0 %

Shares of Anixa Biosciences stock opened at $2.28 on Tuesday. The business’s fifty day moving average price is $2.86 and its 200 day moving average price is $3.03. The stock has a market capitalization of $73.37 million, a P/E ratio of -5.85 and a beta of 0.82. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. As a group, sell-side analysts predict that Anixa Biosciences will post -0.42 EPS for the current year.

Insider Activity at Anixa Biosciences

In other Anixa Biosciences news, CEO Amit Kumar acquired 43,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the transaction, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 22.60% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

Several institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in shares of Anixa Biosciences in the 3rd quarter worth approximately $34,000. Concorde Asset Management LLC purchased a new position in Anixa Biosciences during the second quarter valued at approximately $31,000. Tyler Stone Wealth Management raised its holdings in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after acquiring an additional 21,008 shares in the last quarter. Westside Investment Management Inc. grew its stake in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares in the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.